Business Wire

Pennsylvania Convention Authority Renews ASM Global Management Contract Becoming First Venue in World Leader’s ‘Premier Package’ Convention Center Expansion

24.8.2023 23:46:00 EEST | Business Wire | Press release

Share

The Pennsylvania Convention Center Authority (PCCA) board of directors has approved a five-year contract renewal for ASM Global as its venue management company with the convention center poised as the launch location for a dramatic series of innovations in ASM Global’s convention and conference portfolio — the largest in North America and worldwide.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230824372126/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Photo courtesy of ASM Global.

The new agreement will commence on Dec. 1, 2023, for five years, through Nov. 30, 2028, with the international entertainment leader planning to bring many of its most innovative designs to a leading group of convention centers beginning with PCCA. It will be the first in a program creating unique environments such as immersive LED moments, speed-action offerings to accelerate business strategies, elevated VIP lounges and quiet spaces for business connectivity.

“We are thrilled to announce the continued partnership between the Pennsylvania Convention Center Authority and ASM Global as the venue-management provider for the Pennsylvania Convention Center,” said David A. Nasatir, Esq., chair of the board, PCCA. “For 10 years, ASM Global has been a valued collaborator and, because of their outstanding contributions, has elevated the Pennsylvania Convention Center to world-class status.”

In 2013 the PCCA first made the decision to privatize management of the center with an initial contract being awarded to SMG, which was subsequently rebranded to ASM Global following the 2019 merger of AEG Facilities and SMG. The merger created a venue management powerhouse that spans five continents, 14 countries and more than 350 of the world’s most prestigious arenas, stadiums, theaters and convention centers and has positioned ASM Global as the world’s preeminent venue-management and live-experiences company.

“The ASM Global team at the Pennsylvania Convention Center is, without exception, the finest in the industry,” said John J. McNichol, president and CEO, PCCA. “Their innovative leadership and commitment to delivering an unmatched customer experience have positioned the center, globally, as an industry trailblazer and venue of choice, and we look forward to continuing our collaboration as we take the Pennsylvania Convention Center to the next level.”

Under the management of ASM Global, the Pennsylvania Convention Center has already implemented several cutting-edge and industry-changing initiatives such as the 2014 execution of the Customer Satisfaction Agreement, a document that guides the relationship between the center and the labor unions that work at the facility with the goal of providing a more productive, customer-centric and cost-effective worksite for guests and the ASM Global Acts program, under which the center has successfully executed a robust sustainability and social impact plan.

Dan Hoffend, ASM Global executive vice president, convention centers, said, “We’re excited to begin the next chapter for the convention universe beginning with the Pennsylvania Convention Center. This includes sustainability features that create substantial movement toward carbon neutral; new Flex-space exhibit halls that can adapt to the needs of our diverse attendees; and LED walls that provide sponsorship, wayfinding and entertainment.

“We’re bringing our proven best features from our stadiums and arenas directly to our convention centers to create a premium line of facilities like no other in the industry. Our attendees require entertainment as a part of their business paradigm. We are changing the industry by creating a unique environment for all of our guests,” Hoffend said.

PCC’s ASM Global general manager, Tony Hodgins, said, “We thank the PCCA for their continued trust in our ASM Global team and for their unwavering support over the years. Our team at the center remains focused on our goal of providing a first-class customer experience to all our guests, and we are honored to be able to continue working with our key partners to showcase all that Philadelphia and the Pennsylvania Convention Center have to offer.”

For more information on the Pennsylvania Convention Center community-engagement and outreach initiatives, visit paconvention.com.

About Pennsylvania Convention Center

Pennsylvania Convention Center is located in Center City Philadelphia at the heart of the city's many cultural offerings and world-class dining and entertainment scene. Managed by ASM Global, the center is the 14th largest facility in the nation and features one of the largest exhibit spaces and ballrooms in the Northeastern U.S. The meetings, conventions, trade shows and other events hosted by the center attract attendees from across the country and around the world to Philadelphia, making the facility the largest economic driver of the region’s hospitality industry. For more information, visit paconvention.com.

About ASM Global

ASM Global is the world’s leading producer of entertainment experiences. It is the global leader in venue and event strategy and management, delivering locally tailored solutions and cutting-edge technologies to achieve maximum results for venue owners. The company’s elite venue network spans five continents, with a portfolio of more than 350 of the world’s most prestigious arenas, stadiums, convention and exhibition centers, and performing arts venues. Follow us on Facebook, Instagram, LinkedIn and Twitter. For more information, please visit asmglobal.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jim Yeager
breakwhitelight (for ASM Global)
jim@breakwhitelight.com
818-264-6812

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye